Clinical Trial Update: Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Proliverenol supplementation for non-alcoholic fatty liver disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Proliverenol

Snippet

Sponsor: Dexa Medica Group | Conditions: Non-Alcoholic Fatty Liver Disease (NAFLD) | Phase 2 | Status: COMPLETED